The kinetics of ER fusion protein activation in vivo

Oncogene

Volumn 33, Issue 40, 2014, Pages 4877-4880

  Wilson, C H ^a   Gamper, I ^a   Perfetto, A ^a   Auw, J ^a   Littlewood, T D ^a   Evan, G I ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ESTROGEN RECEPTOR; PROTEIN P53; TAMOXIFEN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN;

ALLELE; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOSENSITIVITY; SPLEEN; THYMUS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; KINETICS; METABOLISM; ORAL DRUG ADMINISTRATION; PANCREAS ISLET; RAT; REPORTER GENE; TRANSCRIPTION INITIATION;

MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; GENES, REPORTER; INJECTIONS, INTRAPERITONEAL; ISLETS OF LANGERHANS; KINETICS; MICE; RATS; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84921795214     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.78     Document Type: Article

References (11)

1. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;23:1686-1690.
2. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999;3:565-577.
3. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M. Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res 1996;24:543-548.
4. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005;37:718-726.
5. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-1075.
6. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991;19:36-43.
7. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002;244:305-318.
8. Ellisor D, Zervas M. Tamoxifen dose response and conditional cell marking: is there control? Mol Cell Neurosci 2010;45:132-138.
9. Feil R, Brocard J, Mascrez B, Le Meur M, Metzger D, Chambon P. Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 1996;93:10887-10890.
10. Hameyer D, Loonstra A, Eshkind L, Schmitt S, Antunes C, Groen A et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics 2007;31:32-41.
11. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002;109:321-334.